Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Meda Acquires Alaven | Contract Pharma

What are you searching for?

Sign in
Breaking News

Meda Acquires Alaven

Specialty pharma builds U.S. footprint with $350 million buy.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Meda has signed an agreement to acquire Alaven, a U.S.-based specialty pharmaceutical company. The acquisition is intended to enhance Meda’s marketing capabilities in the U.S. and expand its therapeutic focus to include both gastroenterology and women’s health, both areas that Meda operates in outside of the U.S.

Alaven also has a strategic OTC platform that accounts for approximately 25% of sales. The OTC business will further diversify Meda’s revenue base in the U.S., as well as serve as a platform for commercializing strategic pipeline opportunities. Overall sales for Alaven were approximately $109 million in 2009. The company has 180 employees, of which 150 are dedicated to marketing and sales. All manufacturing is outsourced to third parties.

Meda will pay $350 million on a cash and debt-free basis, with net debt estimated to be $63 million. The transaction is fully financed by Meda’s existing credit facilities, and is expected to close by early October, pending regulatory review.

“Alaven’s products and business model are very similar to Meda’s and we look forward to integrating their proven capabilities. The acquisition of Alaven enables our operations in the US to become stronger and more profitable by taking advantage of cost and marketing synergies. It is not easy to find U.S. specialty pharma companies of this caliber, therefore we are very pleased,” said Meda’s chief executive officer, Anders Lönner.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters